Listen to this page using ReadSpeaker

Israel Update: Genetic Discovery Highlighted at Retinal Research Conference

Tel Aviv, Israel

Tel Aviv, Israel

Now that I’m back from my trip to Israel, I wanted to offer a couple more posts about my visit, the first covering a fascinating research conference in Tel Aviv.

While attending the Israeli meeting of the Association Research in Vision and Ophthalmology (ARVO), FFB Board member David Brint and I were immediately impressed by Israel’s cutting-edge genetic research. Scientists there are searching for a number of inherited retinal disease genes using state-of-the-art screening technologies and techniques. And the genes they’re after not only affect Israelis, Palestinians and others in the Middle East, but also people in the U.S. and around the world.

We were particularly impressed with Dr. Tamar Ben-Yosef, a knowledgeable and insightful young woman, whose laboratory at Technion University is on the hunt for genetic defects that cause retinitis pigmentosa (RP) and Usher syndrome. She is also working with newly identified RP genes — including MAK and DHDDS — to understand how defects in them cause vision loss. That information will be critical to the development of sight-saving treatments and cures.

Dr. Ben-Yosef told us about her challenging work in understanding an unusual form of RP that causes severe cone degeneration. (RP usually affects both types of photoreceptors, rods and cones, but rods more severely, at least initially.) What’s also unusual is that the disease-causing genetic mutation is found in multiple retinal cell types, including photoreceptors and ganglion cells.

David and I also saw presentations and posters from our good friend Dr. Dror Sharon, an FFB-funded researcher from Hadassah Medical Center, who is studying a number of genes, including CRB1, which is linked to about 10 percent of all Leber congenital amaurosis (LCA) cases in Israelis and Palestinians. In addition to previously discovering the RP gene FAM161A, he continues to investigate the way its affect on rods is different from its impact on cones. That work will ultimately lead to targets for treatments.

Lest anyone think that Hadassah and Technion have a lock on the genetics research in Israel, there were reports on LCA, Usher, different forms of RP (dominant and recessive) and achromatopsia (day blindness) from the Rabin Medical Center, Assaf Harofeh Medical Center, Edith Wolfson Medical Center, Tel Aviv University and Hebrew University School of Veterinary Medicine in Rehovot.

We also learned that age-related macular degeneration (AMD) affects individuals in Israel just like people elsewhere in the developed world, and, as a result, there’s a lot of research into the causes (genetic and non-genetic) and potential treatments. One particularly interesting finding from Dr. Itay Chowers’ group at Hadassah is that one of the primary genetic changes that increases dry AMD risk is found at a higher frequency in the Arabic population than in the Jewish population.

I must say, while the Israeli ARVO wasn’t quite the size of the annual ARVO  conference in the States, the quality of the research was outstanding. In addition to the great genetics work, the science community is also doing outstanding stem cell research, some of which I reported on in my previous post.

Before arriving at the conference, I was concerned about the potential language barrier. I knew that most of the talks were in Hebrew. But, fortunately, the slides and posters were in English. So, while my Hebrew (and David’s) is very rusty, I was able to understand the science, which was some of the best I’ve seen.

Photo courtesy of 

4 Responses to 'Israel Update: Genetic Discovery Highlighted at Retinal Research Conference'

  1. Ina chaitman says:

    Any new treatments or cure for Macula Degeneration and is any vitamin helpful.


    • EyeOnTheCure says:

      Dear Ina, As you may know, researchers with the Age-Related Eye Disease Study (AREDS) reported in 2001 that a nutritional supplement called the AREDS formulation can reduce the risk of developing advanced age-related macular degeneration (AMD). The original AREDS formulation contains vitamin C, vitamin E, beta-carotene, zinc and copper. In 2006, the same research group began a second study called AREDS2 to determine if they could improve the AREDS formulation. They added omega-3 fatty acids, as well as the antioxidants lutein and zeaxanthin. One arm of the study substituted lutein and zeaxanthin for beta-carotene, which prior studies had associated with an increased risk of lung cancer in smokers. The results of AREDS2 showed that while omega-3 fatty acids had no effect on the formulation, lutein and zeaxanthin together appeared to be a safer and more effective alternative to beta-carotene. The bottom line is that if you are in the early stages of AMD, then taking the AREDS2 formula may slow progression by about 25%. For more information on macular degeneration, please see the following web link:

  2. Sabina Mamedova says:

    Hello. My name is Sabina and I am 24. I cant see since birth because my optic nerve did not develop in the womb. My left eye cant see anything but right one sees 5%. My left eye has a strong sense to the light and I can even choose the colours of light when it is closed. My right eye sees as much as I can control myself. In 2010, my right eye had keroplasty operation and the cornea was transplanted. Donor did not fall into my eyes a year later. I saw it better before keroplasty operation but then my eyes became blurred. I just could not see anything and might be blind twice. At the expense of treatments I have a little bit recovered my vision. I am ready to treat my left eye even at the practical level, with gene and stem cell therapy for retinal diseases.Please help me.

    • EyeOnTheCure says:

      Hi Sabina, we suggest you contact a neuro-ophthalmologist. You may want to contact one at an academic research center. FFB only funds research for retinal diseases – not those that affect the optic nerve.

Leave a Reply

Your email address will not be published. Required fields are marked *